$97 M

HTGM Mkt cap, 22-Jun-2018

$4.2 M

HTG Molecular Diagnostics Revenue Q1, 2018
HTG Molecular Diagnostics Gross profit (Q1, 2018)3 M
HTG Molecular Diagnostics Gross profit margin (Q1, 2018), %72.7%
HTG Molecular Diagnostics Net income (Q1, 2018)-5.4 M
HTG Molecular Diagnostics EBIT (Q1, 2018)-5.2 M
HTG Molecular Diagnostics Cash, 31-Mar-201820.5 M

HTG Molecular Diagnostics Financials

HTG Molecular Diagnostics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

4 m5.1 m14.8 m

Revenue growth, %

27%

Cost of goods sold

3.3 m4.1 m5 m

Gross profit

706.1 k996.8 k9.8 m

Gross profit Margin, %

17%19%66%

R&D expense

4.6 m7.9 m10 m

General and administrative expense

15 m17.4 m17.5 m

Operating expense total

19.6 m25.3 m27.5 m

EBIT

(18.9 m)(24.3 m)(17.7 m)

EBIT margin, %

(467%)(474%)(120%)

Interest expense

1.7 m1.9 m1.3 m

Interest income

85.9 k112.4 k73.2 k

Pre tax profit

(21.4 m)(26 m)(19 m)

Income tax expense

10.2 k10.1 k2.9 k

Net Income

(21.4 m)(26 m)(19 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

790.6 k1 m865.2 k1.9 m913.9 k1.4 m1.8 m4.2 m

Cost of goods sold

834.9 k809 k843.5 k933 k1.1 m1.3 m1.2 m1.1 m

Gross profit

(44.4 k)201.9 k21.8 k962.8 k(211.1 k)75.9 k523.9 k3 m

Gross profit Margin, %

(6%)20%3%51%(23%)6%30%73%

R&D expense

953.2 k1.3 m2 m2.6 m1.9 m1.3 m1.6 m2.6 m

General and administrative expense

3.7 m3.7 m4.7 m4.7 m3.9 m4.2 m4.4 m5.7 m

Operating expense total

4.7 m5 m6.7 m7.3 m5.8 m5.5 m6 m8.2 m

EBIT

(4.7 m)(4.8 m)(6.7 m)(6.4 m)(6.1 m)(5.4 m)(5.5 m)(5.2 m)

EBIT margin, %

(598%)(477%)(770%)(336%)(663%)(396%)(313%)(126%)

Interest expense

476.1 k378.7 k392.5 k538.9 k490.8 k398.4 k350.1 k182.5 k

Interest income

11.1 k37.8 k35.5 k31.1 k26.2 k12.1 k17.6 k133.2 k

Pre tax profit

(6.5 m)(5.2 m)(7 m)(6.9 m)(6.5 m)(5.8 m)(5.8 m)(5.4 m)

Income tax expense

3.4 k860 4.3 k280 860

Net Income

(6.5 m)(5.2 m)(7 m)(6.9 m)(6.5 m)(5.8 m)(5.8 m)(5.4 m)

HTG Molecular Diagnostics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

3.3 m7.5 m10 m

Accounts Receivable

716.2 k1.4 m6.4 m

Current Assets

34.9 m15.1 m17.9 m

PP&E

1.9 m3.3 m3.3 m

Total Assets

39.4 m18.5 m21.3 m

Accounts Payable

724.8 k761.7 k2.4 m

Current Liabilities

6.3 m10 m13.3 m

Total Liabilities

24 m24.3 m

Additional Paid-in Capital

106.6 m110.1 m131.5 m

Retained Earnings

(89.6 m)(115.6 m)(134.6 m)

Total Equity

16.9 m(5.6 m)(3.1 m)

Financial Leverage

2.3 x-3.3 x-6.9 x

Quarterly

USDQ1, 2018

Cash

20.5 m

Accounts Receivable

2.8 m

Current Assets

50.2 m

PP&E

3.1 m

Total Assets

53.3 m

Accounts Payable

2.2 m

Current Liabilities

5.1 m

Total Liabilities

22.4 m

Additional Paid-in Capital

170.9 m

Retained Earnings

(139.9 m)

Total Equity

31 m

Financial Leverage

1.7 x

HTG Molecular Diagnostics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(21.4 m)(26 m)(19 m)

Depreciation and Amortization

662.6 k1.5 m1.2 m

Accounts Receivable

40 k(661.2 k)(5 m)

Inventories

(746.2 k)(33.2 k)77.2 k

Accounts Payable

(312.3 k)10.1 k1.2 m

Cash From Operating Activities

(19.2 m)(22.2 m)(16.6 m)

Purchases of PP&E

(1.3 m)(1.9 m)(1 m)

Cash From Investing Activities

(32.2 m)24.4 m3.3 m

Cash From Financing Activities

51.1 m2 m15.8 m

Interest Paid

935 k1.1 m698.1 k

Income Taxes Paid

2 k

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(6.5 m)(5.2 m)(7 m)(6.9 m)(6.5 m)(5.8 m)

Accounts Receivable

852.3 k554.2 k696.8 k574.6 k1.9 m591.9 k1.2 m1.6 m

Accounts Payable

879 k1.2 m966.9 k2.2 m1.6 m1.1 m1.2 m1.3 m

HTG Molecular Diagnostics Ratios

USDY, 2018

Financial Leverage

1.7 x
Report incorrect company information